Benralizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Benralizumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD125
Clinical data
Legal status investigational
Identifiers
CAS number 1044511-01-4 N
ATC code None
UNII 71492GE1FX YesY
KEGG D09874 N
Chemical data
Formula C6492H10060N1724O2028S42 
Mol. mass 146.0 kDa
 N (what is this?)  (verify)

Benralizumab (INN) is a monoclonal antibody which is being developed by MedImmune for the treatment of asthma. It is directed against the alpha-chain of the interleukin-5 receptor (CD125).[1][2]

References[edit]

  1. ^ Statement on an Nonproprietary Name adopted by the USAN Counil: Benralizumab
  2. ^ Catley, M. C. (2010). "Asthma & COPD--IQPC's Second Conference". IDrugs : the investigational drugs journal 13 (9): 601–604. PMID 20799138.  edit